| 1 |
32682874 | ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. | 2021 Jan 10 |
1 |
| 2 |
33400943 | Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. | 2021 Jul 13 |
1 |
| 3 |
31359271 | Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes. | 2020 Jan |
2 |
| 4 |
32476097 | Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. | 2020 May 31 |
2 |
| 5 |
32519344 | CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis. | 2020 Jul |
3 |
| 6 |
31000417 | Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. | 2019 May |
1 |
| 7 |
30093744 | A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia. | 2018 Jul-Aug |
1 |
| 8 |
26780783 | Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. | 2017 Mar |
3 |
| 9 |
27738718 | Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. | 2017 Jan |
1 |
| 10 |
28133766 | Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. | 2017 Jul |
1 |
| 11 |
26418700 | Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. | 2016 Feb |
1 |
| 12 |
26514968 | Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. | 2016 Feb |
2 |
| 13 |
26944100 | Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. | 2016 Apr |
2 |
| 14 |
27145399 | Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. | 2016 Nov |
1 |
| 15 |
27942231 | CYP2D6 polymorphisms and their influence on risperidone treatment. | 2016 |
1 |
| 16 |
26129906 | Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. | 2015 Dec |
1 |
| 17 |
26387027 | Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. | 2015 Nov |
1 |
| 18 |
22623266 | Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. | 2012 Aug |
6 |
| 19 |
22929407 | Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. | 2012 Oct |
2 |
| 20 |
28520384 | Risperidone Therapy and CYP2D6 Genotype | 2012 |
1 |
| 21 |
21387786 | [The review of acute risperidone poisoning]. | 2010 |
2 |
| 22 |
19387994 | Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. | 2009 Jun |
1 |
| 23 |
19440082 | Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. | 2009 Jun |
1 |
| 24 |
19910717 | Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. | 2009 Dec |
2 |
| 25 |
18708991 | ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. | 2008 Oct |
2 |
| 26 |
18728628 | Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. | 2008 Oct |
3 |
| 27 |
17541883 | A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. | 2007 May |
1 |
| 28 |
17715206 | Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. | 2007 Nov |
1 |
| 29 |
16833023 | Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. | 2006 Jun |
2 |
| 30 |
15565299 | Risperidone plasma levels, clinical response and side-effects. | 2005 Aug |
2 |
| 31 |
16321618 | Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. | 2005 Nov |
2 |
| 32 |
15089809 | Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. | 2004 May |
1 |
| 33 |
15260906 | QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. | 2004 Jun |
2 |
| 34 |
15270204 | The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. | 2004 Aug |
5 |
| 35 |
12616663 | Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. | 2003 Feb |
4 |
| 36 |
12107617 | Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. | 2002 Jun |
1 |
| 37 |
12518271 | Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. | 2002 Nov |
1 |
| 38 |
11360029 | Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. | 2001 Jun |
1 |
| 39 |
11560868 | Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. | 2001 Oct |
4 |
| 40 |
11791898 | Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. | 2001 Nov |
2 |
| 41 |
10771452 | Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. | 2000 |
2 |
| 42 |
10048600 | Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. | 1999 Feb |
2 |
| 43 |
10453802 | A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. | 1999 Jul |
2 |
| 44 |
10639689 | Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. | 1999 Dec |
8 |
| 45 |
7545821 | A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. | 1995 Jun |
1 |
| 46 |
7690693 | Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. | 1993 Sep |
1 |